Public Company

Frequency Therapeutics

Working to advance regenerative medicine and develop a therapeutic to restore hearing for those with the most common form of hearing loss.


We are a clinical-stage biotechnology company focused on restoring function – first in hearing loss and then in multiple sclerosis – by developing therapeutics that activate a person’s innate regenerative potential within the body. Our proprietary approach, progenitor cell activation (PCA), uses small molecules to activate progenitor cells within the body to create functional tissue. Our initial therapeutic focus is sensorineural hearing loss (SNHL), which accounts for 90 percent of all hearing loss. SNHL is typically caused by the permanent loss of sensory hair cells in the cochlea within the ear. FX-322, our lead product candidate, is designed to regenerate hair cells through the activation of progenitor cells already present in the cochlea. Applying the same underlying science and approach we use to regenerate sensory hair cells in the inner ear, Frequency also seeks to activate existing progenitor cells in patients with multiple sclerosis to remyelinate axons and restore signal transmission. Our scientists are following early restorative signals in preclinical studies.


Founded 2015
Type Public
Longevity related Yes
Location Lexington, Massachusetts, USA

Latest News